Literature DB >> 32965016

Advances in SARS-CoV-2: a systematic review.

Y-X Bai1, Y-H Xu, X Wang, C Sun, Y Guo, S Qiu, K-W Ma.   

Abstract

OBJECTIVE: In December 2019, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection broke out in Wuhan, China. However, we still lack a comprehensive understanding of this emerging virus. In this manuscript, we collected relevant articles and reviewed the characteristics about SARS-CoV-2.
MATERIALS AND METHODS: We performed an online search on PubMed and Web of Science with the keywords COVID-19, 2019-nCoV and SARS-CoV-2, and summarized the epidemiology, virology, clinical features and treatments of SARS-CoV-2 infection.
RESULTS: We retrieved 157 published papers about SARS-CoV-2 from January, 2020 to April, 2020. We found that SARS-CoV-2 was a kind of virus with low mortality rate and high infectivity. This virus can enter human cells through angiotensin-converting enzyme 2 (ACE2) in alveoli and activate immune response in human body. SARS-CoV-2 infection can be classified as asymptomatic, mild, common, severe, and critical. We summarized antiviral drugs against SARS-CoV-2, such as remdesivir, hydroxychloroquine and favipiravir. Because the vaccine of SARS-CoV-2 is developing, more clinical studies are needed to verify the safety and efficacy of these treatments.
CONCLUSIONS: SARS-CoV-2 is a novel coronavirus that has caused a global pandemic. We should pay more attention to prevent SARS-CoV-2 and try to control it sooner.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32965016     DOI: 10.26355/eurrev_202009_22873

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  4 in total

1.  Homologous and Heterologous Anti-COVID-19 Vaccination Does Not Induce New-Onset Formation of Autoantibodies Typically Accompanying Lupus Erythematodes, Rheumatoid Arthritis, Celiac Disease and Antiphospholipid Syndrome.

Authors:  Christoph Thurm; Annegret Reinhold; Katrin Borucki; Sascha Kahlfuss; Eugen Feist; Jens Schreiber; Dirk Reinhold; Burkhart Schraven
Journal:  Vaccines (Basel)       Date:  2022-02-18

Review 2.  Translational Control of COVID-19 and Its Therapeutic Implication.

Authors:  Dejiu Zhang; Lei Zhu; Yin Wang; Peifeng Li; Yanyan Gao
Journal:  Front Immunol       Date:  2022-03-29       Impact factor: 7.561

Review 3.  Research progress of biosensors for detection of SARS-CoV-2 variants based on ACE2.

Authors:  Hongshuai Wei; Congcong Zhang; Xin Du; Zhenguo Zhang
Journal:  Talanta       Date:  2022-08-06       Impact factor: 6.556

4.  Harnessing Artificial Intelligence to assess the impact of nonpharmaceutical interventions on the second wave of the Coronavirus Disease 2019 pandemic across the world.

Authors:  Sile Tao; Nicola Luigi Bragazzi; Jianhong Wu; Bruce Mellado; Jude Dzevela Kong
Journal:  Sci Rep       Date:  2022-01-18       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.